Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Tóm tắt
Từ khóa
Tài liệu tham khảo
Eichenfield, 2014, Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies, J Am Acad Dermatol, 71, 116, 10.1016/j.jaad.2014.03.023
Odhiambo, 2009, Global variations in prevalence of eczema symptoms in children from ISAAC phase three, J Allergy Clin Immunol, 124, 1251, 10.1016/j.jaci.2009.10.009
Arkwright, 2013, Management of difficult-to-treat atopic dermatitis, Journal of Allergy Clin Immunol Pract, 1, 142, 10.1016/j.jaip.2012.09.002
Blume-Peytavi, 2012, Atopic dermatitis in children: management of pruritus, J Eur Acad Dermatol Venereol, 26, 2, 10.1111/j.1468-3083.2012.04710.x
Mollanazar, 2015, Mediators of chronic pruritus in atopic dermatitis: getting the itch out?, Clin Rev Allergy Immunol
Schneider, 2013, Atopic dermatitis: a practice parameter update 2012, J Allergy Clin Immunol, 131, 295, 10.1016/j.jaci.2012.12.672
Ellis, 2002, Cost of atopic dermatitis and eczema in the United States, J Am Acad Dermatol, 46, 361, 10.1067/mjd.2002.120528
Margolis, 2014, Persistence of mild to moderate atopic dermatitis, JAMA Dermatol, 150, 593, 10.1001/jamadermatol.2013.10271
Carr, 2013, Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations, Paediatr Drugs, 15, 303, 10.1007/s40272-013-0013-9
Siegfried, 2013, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am J Clin Dermatol, 14, 163, 10.1007/s40257-013-0020-1
Walling, 2010, Update on the management of chronic eczema: new approaches and emerging treatment options, Clin Cosmet Investig Dermatol, 3, 99, 10.2147/CCID.S6496
Jimenez, 2001, Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation, J Pharmacol Exp Ther, 299, 753
Baumer, 2007, Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis, Inflamm Allergy Drug Targets, 6, 17, 10.2174/187152807780077318
Grewe, 1982, Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness, J Allergy Clin Immunol, 70, 452, 10.1016/0091-6749(82)90008-2
Heskel, 1984, Elevated umbilical cord blood leukocyte cyclic adenosine monophosphate-phosphodiesterase activity in children with atopic parents, J Am Acad Dermatol, 11, 422, 10.1016/S0190-9622(84)70184-8
Butler, 1983, Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis, J Allergy Clin Immunol, 71, 490, 10.1016/0091-6749(83)90467-0
Hanifin, 1990, Phosphodiesterase and immune dysfunction in atopic dermatitis, J Dermatol Sci, 1, 1, 10.1016/0923-1811(90)90003-V
Hanifin, 1996, Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis, J Invest Dermatol, 107, 51, 10.1111/1523-1747.ep12297888
Moustafa, 2014, A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology, Dermatol Online J, 20, 22608, 10.5070/D3205022608
Wittmann, 2013, Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases, Dermatol Ther (Heidelb), 3, 1, 10.1007/s13555-013-0023-0
Jarnagin, 2016, Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis, J Drugs Dermatol, 15, 390
Akama, 2009, Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis, Bioorg Med Chem Lett, 19, 2129, 10.1016/j.bmcl.2009.03.007
Dastidar, 2007, Therapeutic benefit of PDE4 inhibitors in inflammatory diseases, Curr Opin Investig Drugs, 8, 364
Freund, 2012, Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center, FEBS Lett, 586, 3410, 10.1016/j.febslet.2012.07.058
Nazarian, 2009, AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis, Curr Opin Investig Drugs, 10, 1236
Jimenez, 2004, Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes, Cell Signal, 16, 1363, 10.1016/j.cellsig.2004.04.002
Zane, 2016, Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies, Future Med, 8, 853
Zane, 2016, AN2728 Topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study, Pediatr Dermatol, 10.1111/pde.12872
Murrell, 2015, Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2A, vehicle-controlled, proof-of-concept study, J Drugs Dermatol, 14, 1108
Stein Gold, 2015, A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis, J Drugs Dermatol, 14, 1394
Tom, 2016, Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study, Pediatr Dermatol, 33, 150, 10.1111/pde.12780
Hanifin, 1980, Diagnostic features of atopic dermatitis, Acta Dermatol Venereol, 92, 44, 10.2340/00015555924447
Garcia, 2012, Frontiers of rapid itch relief: a review of methylprednisolone aceponate, J Eur Acad Dermatol Venereol, 26, 9
Schachner, 2005, Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study, Pediatrics, 116, e334, 10.1542/peds.2004-2638
Callen, 2007, A systematic review of the safety of topical therapies for atopic dermatitis, Br J Dermatol, 156, 203, 10.1111/j.1365-2133.2006.07538.x
2000
2001
Berth-Jones, 2003, Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study, BMJ, 326, 1367, 10.1136/bmj.326.7403.1367
Sobell, 2016, Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis, Acta Derm Venereol, 96, 514, 10.2340/00015555-2360
Stull, 2015, Advances in therapeutic strategies for the treatment of pruritus, Expert Opin Pharmacother, 1-17, 671
Andoh, 2014, Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis, Exp Dermatol, 23, 359, 10.1111/exd.12377
Wakita, 2015, A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fiber nerves, Exp Dermatol, 24, 215, 10.1111/exd.12606